Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It has demonstrated efficacy in the treatment of metastatic non-small cell lung cancer (NSCLC) with positive EGFR mutations. This drug has been launched in China and successfully included in the national medical insurance catalog. The generic version of Dacomitinib produced by Everest Pharmaceuticals in Bangladesh is available in a specification of 45mg*30 tablets, with a price of approximately 858 US dollars per box.

How much does Dacomitinib cost?

The price of Dacomitinib varies depending on different versions and specifications. Currently, the main products available on the market include the original research drug of Pfizer (exported to India), as well as generic versions produced by Everest Pharmaceuticals (Bangladesh) and Lucius Pharmaceuticals (Laos).

Price

The original research drug of Pfizer (exported to India) comes in a specification of 45mg*30 capsules, with a price of approximately 858 US dollars per box. The above price is for reference only.

Reasons for Price Differences

The price differences of Dacomitinib mainly stem from factors such as production costs, R&D investment, market positioning, and disparities in economic development levels across regions. The original research drug requires substantial investment in R&D and production, resulting in a relatively higher price. In contrast, generic drugs are available at a lower price for patients by reducing production and R&D costs.

Purchase Channels for Dacomitinib

The main purchase channels for Dacomitinib include hospital pharmacies and specialized pharmacies.

Hospital Pharmacies

Hospital pharmacies are one of the formal channels for purchasing Dacomitinib. Under the guidance of doctors, patients can purchase Dacomitinib through hospital pharmacies via formal channels. The drugs in hospital pharmacies are of qualified quality, but their prices may be relatively higher.

Specialized Pharmacies

Specialized pharmacies are also important channels for purchasing Dacomitinib. These pharmacies usually have a rich reserve of drugs and a professional team of pharmacists, who can provide patients with medication consultation and guidance. The prices of specialized pharmacies are more flexible compared to hospital pharmacies, allowing patients to choose Dacomitinib of different brands and specifications according to their own needs.

Efficacy of Dacomitinib

Dacomitinib has shown significant efficacy in the treatment of metastatic NSCLC with positive EGFR mutations. It achieves the therapeutic effect by irreversibly inhibiting the activity of EGFR tyrosine kinase, thereby blocking the growth and proliferation of tumor cells.

Clinical Trial Results

Results from multiple clinical trials have shown that, compared with traditional chemotherapy drugs, Dacomitinib can significantly improve the progression-free survival (PFS) and overall survival (OS) of NSCLC patients with positive EGFR mutations. The adverse reactions of Dacomitinib are also relatively controllable, and the quality of life of patients is improved.

Indications and Targets

The indications of Dacomitinib mainly include metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutation detected by FDA-approved tests. Its targets include not only EGFR (HER1) but also HER2 and HER4. This enables Dacomitinib to more comprehensively inhibit the growth and proliferation of tumor cells during treatment.

The adverse reactions of Dacomitinib are also relatively mild, allowing patients to tolerate the treatment process well.